Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Details)

v2.4.0.8
Discontinued Operations (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2007
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 32.00%    
Other Asset Impairment Charges   $ 700,000  
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]      
Asset Impairment Charges 0 23,517,000  
Facilities realignment 0 706,000 1,000,000
Severance Costs 0 0  
Liabilities Subject to Compromise, Period Increase (Decrease) [Roll Forward]      
Accrued Liability at beginning of the period 5,000 [1] 1,120,000  
Add: Costs incurred, excluding non-cash charges 0 0  
Payments for Postemployment Benefits (5,000) (1,115,000)  
Accrued Liability at end of the period 0 [1] 5,000 [1]  
Net Income (Loss) Attributable to Parent [Abstract]      
Revenue, net 0 0  
Loss from discontinued operations, before income tax (44,000) (51,000)  
Income tax expense 5,000 8,000  
Loss from discontinued operations, net of tax (49,000) (59,000)  
Disposal Group, Including Discontinued Operation, Classified Balance Sheet Disclosures [Abstract]      
Current assets 0 14,000  
Non-current assets 150,000 150,000  
Total assets 150,000 164,000  
Current liabilities 405,000 368,000  
Non-current liabilities 619,000 1,006,000  
Total liabilities $ 1,024,000 $ 1,374,000  
[1] Accrued liability at December 31, 2012 consists of Pharmakon employee severance costs.